Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers
Bo Gao(Sun Yat-sen University), Oliver Klein(Berlin-Brandenburger Centrum für Regenerative Therapien), Craig Underhill(AstraZeneca (United Kingdom)), Anne Hamilton(Royal Women's Hospital), Rosemary Harrup(University of Tasmania), Henry Marshall(Wellcome Sanger Institute), Ashray Gunjur(Wellcome Sanger Institute), Damien Kee(Peter MacCallum Cancer Centre), Jonathan Cebon(La Trobe University), Yoland Antill(Peninsula Health), John P. Grady(Garvan Institute of Medical Research), Won-Hee Yoon(Westmead Hospital), Jane So(Auckland City Hospital), Mandy L. Ballinger(Garvan Institute of Medical Research), Matteo S. Carlino(The University of Sydney), Elnaz Tavancheh(Olivia Newton-John Cancer Wellness & Research Centre), Michael Michael(Ospedale San Donato), Jodie Palmer(Olivia Newton-John Cancer Wellness & Research Centre), Howard Chan(Calvary Mater Newcastle Hospital), Wei‐Sen Lam(Fiona Stanley Hospital)
Cited by 18
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k